SGD Pharma, announces its commitment to company-wide emissions reductions as part of its decarbonization strategy by joining the Science Based Targets initiative (SBTi).

Armis Biopharma, Inc. announced that the company received a $20.3 million contract from the Defense Threat Reduction Agency (DTRA) to develop its proprietary Veriox® DECON chemical warfare agent (CWA) decontamination product.

Consortium aims to share best practices and increase our understanding of genetic disease.

Laverock Therapeutics secures £1m funding via the Innovate UK Investor Partnerships Future Economy programme, supported by UKI2S.

Aiming to improve exosome purification process that is currently slowing adoption of promising gene therapies and other new modalities.

Expanded footprint, new capabilities mark IDT’s entrance into CRISPR therapeutics space.

At its Capital Markets Day in Visp (CH), Lonza shared a detailed update on its strategic priorities and provided new Mid-Term Guidance for 2024 to 2028.

Lonza, announced the extension of a collaboration with a major biopharmaceutical partner for the commercial-scale filling of ADCs.

At the 2023 Grand Challenges Annual Meeting, Bill Gates, announced new investments to advance access to mRNA research and vaccine manufacturing technology that will support low- and middle-income countries.

Takara Bio Inc. announces that it has entered into a License Agreement with non-profit/charity organization, Fondazione Telethon ETS Italy, under which Takara Bio grants Telethon a commercial license to use RetroNectin®.